Association between multiple myeloma and acute myeloid leukemia secondary to myelodysplastic syndrome

2013 ◽  
Vol 71 (5) ◽  
pp. 581-584
Author(s):  
Selim Jennane ◽  
Hicham Eddou ◽  
El Mehdi Mahtat ◽  
Johanna Konopacki ◽  
Bertrand Souleau ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Acute Myeloid

scholarly journals High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma

Haematologica ◽  
2010 ◽  
Vol 95 (7) ◽  
pp. 1191-1197 ◽  
Author(s):  
J. Greiner ◽  
A. Schmitt ◽  
K. Giannopoulos ◽  
M. T. Rojewski ◽  
M. Gotz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
High Dose ◽  
Peptide Vaccination ◽  
Acute Myeloid

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Blood ◽  
2008 ◽  
Vol 111 (3) ◽  
pp. 1357-1365 ◽  
Author(s):  
Michael Schmitt ◽  
Anita Schmitt ◽  
Markus T. Rojewski ◽  
Jinfei Chen ◽  
Krzysztof Giannopoulos ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cells ◽  
Acute Myeloid Leukemia ◽  
Myelodysplastic Syndrome ◽  
Myeloid Leukemia ◽  
Cell Epitope ◽  
Peptide Vaccination ◽  
Specific Lysis ◽  
Clinical Responses ◽  
Acute Myeloid

Abstract The receptor for hyaluronic acid–mediated motility (RHAMM) is an antigen eliciting both humoral and cellular immune responses in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). We initiated a phase 1 clinical trial vaccinating 10 patients with R3 (ILSLELMKL), a highly immunogenic CD8+ T-cell epitope peptide derived from RHAMM. In 7 of 10 patients, we detected an increase of CD8+/HLA-A2/RHAMM R3 tetramer+/CD45RA+/CCR7−/CD27−/CD28− effector T cells in accordance with an increase of R3-specific CD8+ T cells in enzyme linked immunospot (ELISpot) assays. In chromium release assays, a specific lysis of RHAMM-positive leukemic blasts was shown. Three of 6 patients with myeloid disorders (1/3 AML, 2/3 MDS) achieved clinical responses: one patient with AML and one with MDS showed a significant reduction of blasts in the bone marrow after the last vaccination. One patient with MDS no longer needed erythrocyte transfusions after 4 vaccinations. Two of 4 patients with MM showed a reduction of free light chain serum levels. Taken together, RHAMM-R3 peptide vaccination induced both immunologic and clinical responses, and therefore RHAMM constitutes a promising target for further immunotherapeutic approaches. This study is registered at http://ISRCTN.org as ISRCTN32763606 and is registered with EudraCT as 2005-001706-37.

Sign in / Sign up

Export Citation Format

Share Document